Key statistics dashboard for Acrivon Therapeutics, Inc. Common Stock (ACRV). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool.
Stock Data
| Price | $1.70 |
| Market Cap | $73M |
| Beta | 1.74 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.90 |
| Price / Book | 0.82 |
| P/S | 0.00 |
| P/FCF | -1.13 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 7.99 |
| Quick Ratio | 7.99 |
| Cash Ratio | 3.62 |
| Debt / Equity | 0.02 |
| Debt / Assets | 2.13% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -0.90 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 2.07 |
| Cash per share | 2.15 |
| FCF per share | -1.53 |
| Tangible Book Value per share | 2.07 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 10 |
| Avg rating (1-5) | 0.90 |
Related companies: ATYR · BMEA · CBUS · IMUX · PMVP · RLMD · RPTX
Explore sector: Healthcare · Biotechnology
More sections of ACRV: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks